[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631074":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":39,"locations":44,"responsibleParty":108,"collaborators":111,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":26,"eligibilityCriteria":121,"healthyVolunteers":117,"sex":122,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":26,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":152,"whyStopped":26,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"Haydarpasa Numune Training and Research Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo Plus Standard Treatment","PLACEBO_COMPARATOR","Participants will receive matching placebo orally at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and\u002For duloxetine.",[13],"Other: Placebo syrup",{"label":15,"type":16,"description":17,"interventionNames":18},"FibroThol Plus Standard Treatment","EXPERIMENTAL","Participants will receive FibroThol, an oral supplement containing 2-Aticyto Complex and D-ribose, at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and\u002For duloxetine.",[19],"Dietary Supplement: 2-Aticyto Complex and D-ribose Oral Supplement",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","2-Aticyto Complex and D-ribose Oral Supplement","An oral dietary supplement containing 2-Aticyto Complex and D-ribose (marketed as FibroThol). In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and\u002For duloxetine.",[15],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo syrup","A matching oral placebo syrup without active study ingredients. In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and\u002For duloxetine. The placebo contains deionized water, glycerol, sodium alginate, xanthan gum, steviol glycosides, raspberry flavor, pineapple flavor, strawberry flavor, and mint flavor.",[9],[32,36],{"name":33,"affiliation":34,"role":35},"Kubra Neslihan Kurt Oktay, MD","University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":34,"role":38},"Kubra Nesihan Kurt Oktay, MD","STUDY_CHAIR",[40],{"name":33,"role":41,"phone":42,"phoneExt":26,"email":43},"CONTACT","+905352916609","drneslihankurt@gmail.com",[45,62,73,86,97],{"facility":34,"status":26,"city":46,"state":46,"zip":47,"country":48,"countryCode":26,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Istanbul","34662","Turkey (Türkiye)",{"type":50,"coordinates":51},"Point",[52,53],28.94966,41.01384,{"lat":53,"lon":52},[56,57,60],{"name":33,"role":41,"phone":42,"phoneExt":26,"email":43},{"name":58,"role":59,"phone":26,"phoneExt":26,"email":26},"Arzu Erbilici, MD","SUB_INVESTIGATOR",{"name":61,"role":59,"phone":26,"phoneExt":26,"email":26},"Duygu Geler Kulcu, MD",{"facility":63,"status":26,"city":46,"state":26,"zip":64,"country":48,"countryCode":26,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation","34480",{"type":50,"coordinates":66},[52,53],{"lat":53,"lon":52},[69],{"name":70,"role":41,"phone":71,"phoneExt":26,"email":72},"Fatih Bagcıer, MD","+905442429042","bagcier_42@hotmail.com",{"facility":74,"status":26,"city":46,"state":26,"zip":75,"country":48,"countryCode":26,"cosmosGeoPoint":76,"geoPoint":78,"contacts":79},"University of Health Sciences, Sultan Abdulhamid Han Training and Research Hospital, Department of Physical Medicine and Rehabilitation","34668",{"type":50,"coordinates":77},[52,53],{"lat":53,"lon":52},[80,84],{"name":81,"role":41,"phone":82,"phoneExt":26,"email":83},"Mustafa Hüseyin Temel, MD","+905342714872","mhuseyintemel@gmail.com",{"name":85,"role":59,"phone":26,"phoneExt":26,"email":26},"Emre Ata, MD",{"facility":87,"status":26,"city":46,"state":26,"zip":88,"country":48,"countryCode":26,"cosmosGeoPoint":89,"geoPoint":91,"contacts":92},"Erenkoy Physical Therapy and Rehabilitation Hospital, Department of Physical Medicine and Rehabilitation","34732",{"type":50,"coordinates":90},[52,53],{"lat":53,"lon":52},[93],{"name":94,"role":41,"phone":95,"phoneExt":26,"email":96},"Sefa Kurt, MD","+905385159528","sefa.kurt@yahoo.com",{"facility":98,"status":26,"city":46,"state":26,"zip":99,"country":48,"countryCode":26,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},"University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Physical Medicine and Rehabilitation","34752",{"type":50,"coordinates":101},[52,53],{"lat":53,"lon":52},[104],{"name":105,"role":41,"phone":106,"phoneExt":26,"email":107},"Ozge Gulsum Illeez, MD","+905326255684","ozgeilleez@gmail.com",{"type":35,"investigatorFullName":109,"investigatorTitle":110,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Kubra Neslihan Kurt Oktay","MD",[112],{"name":113,"class":114},"Almediko Saglik Urunleri Turizm Gida Sanayi ve Ticaret Limited Sirketi","INDUSTRY","100631074","effects-of-2-aticyto-complex-and-d-ribose-on-pain-and-clinical-course-in-patients-with-fibromyalgia-100631074",false,"NCT07495943","Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia","Effects of 2-Aticyto Complex and D-Ribose on Pain, Symptoms, and Clinical Course in Patients With Fibromyalgia Syndrome","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria\n* Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year\n* Receiving pregabalin and\u002For duloxetine treatment for at least 3 months\n* Able to live independently in the community\n* Literate and able to record symptoms and responses\n* No cognitive dysfunction that would interfere with answering study questions\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Rheumatologic disease\n* Renal failure\n* Hepatic failure\n* Cardiovascular disease\n* Hypoglycemia or diabetes mellitus\n* Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease)\n* Known allergy or hypersensitivity to any active or excipient component of the study syrup\n* Use of any other dietary supplement or nutritional support product during the study period\n* Pregnancy or lactation\n* Active malignancy\n* Active infection\n* Severe psychiatric disease that may interfere with study participation or assessment\n* Refusal to participate or inability to provide informed consent","ALL","18 Years","65 Years",{"count":126,"type":127},200,"ESTIMATED","INTERVENTIONAL",[130],"NA","This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and\u002For duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.",[133,134],"Fibromyalgia Syndrome","Fibromyalgia",[134,133,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151],"2-Aticyto Complex","D-ribose","FibroThol","Dietary Supplement","Placebo-Controlled","Randomized","Double-Blind","Multicenter Study","Pregabalin","Duloxetine","Pain","Fatique","Sleep Quality","Depression","Anxiety","Quality of Life","NOT_YET_RECRUITING","2026-03-26",{"date":155,"type":156},"2026-04-01","ACTUAL",{"date":158,"type":127},"2026-05-04",{"date":160,"type":127},"2027-05-04",{"name":5,"class":6},5]